Recent advances in the treatment of acromegaly

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 4, 2009, Pages 304-307

  Aghi, Manish ^a   Blevins Jr , Lewis S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Acromegaly; Growth hormone receptor antagonist; Lanreotide; Octreotide; Pegvisomant; Radiosurgery; Somatostatin receptor analogs; Transphenoidal surgery

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOPEPTIN; ASPARTATE AMINOTRANSFERASE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN BINDING PROTEIN 1; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CYBERKNIFE; DISEASE CONTROL; DNA DAMAGE; GAMMA KNIFE RADIOSURGERY; GROWTH HORMONE RELEASE; HEADACHE; HUMAN; LIFE EXPECTANCY; LOW DRUG DOSE; PHYSICIAN; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE; REMISSION; REVIEW; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME;

ACROMEGALY; DRUG THERAPY, COMBINATION; HUMAN GROWTH HORMONE; HUMANS; LIFE EXPECTANCY; QUALITY OF LIFE;

EID: 67651096204     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32832d88e4     Document Type: Review

References (18)

1. Castinetti F, Morange I, Dufour H, et al. Radiotherapy and radiosurgery in acromegaly. Pituitary 2008 [Epub ahead of print]
2. Laws ER. Surgery for acromegaly: evolution of the techniques and outcomes. Rev Endocr Metab Disord 2008; 9:67-70.
3. Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly: is there still a place for radiotherapy? Pituitary 2007; 10:53-59.
4. Pollock BE, Jacob JT, Brown PD, Nippoldt TB. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 2007; 106:833-838.
5. Vik-Mo EO, Oksnes M, Pedersen PH, et al. Gamma knife stereotactic radio-surgery for acromegaly. Eur J Endocrinol 2007; 157:255-263. (Pubitemid 47603528)
6. Losa M, Gioia L, Picozzi P, et al. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 2008; 93:2546-2552. (Pubitemid 352008518)
7. Petit JH, Biller BM, Coen JJ, et al. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract 2007; 13:726-734.
8. Roberts BK, Ouyang DL, Lad SP, et al. Efficacy and safety of CyberKnife radiosurgery for acromegaly. Pituitary 2007; 10:19-25.
9. Jagannathan J, Sheehan JP, Pouratian N, et al. Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery 2008; 62:1262-1269; discussion 1269-1270.
10. Ludecke D, Abe T. Transsphenoidal microsurgery for nearly diagnosed acromegaly: a personal view after more than 1000 operations. Neuroendocrinol 2006; 83:230-239. This review focuses on the possibilities and limits of pituitary surgery in acromegaly. The author relates his extensive experience in providing considerable insight into the surgical management of patients with acromegaly and at a time of evolving technologies. (Pubitemid 44578877)
11. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective randomized trial. J Clin Endocrinol Metab 2008; 93:2984-2990. The concept of pretreatment of patients with growth hormone secreting macroadenomas with somatostatin analogs is one that requires further study. This manuscript, however, suggests that preoperative octreotide treatment may indeed improve the surgical cure rate in newly diagnosed patients with macroadenomas.
12. Karavitaki N, Turner HE, Adams CBT, et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol 2008; 68:970-975. (Pubitemid 351703951)
13. Chanson P, Borson-Chazot, Kuhn J-M, et al. Control of the IGF-I levels with titrated doses of lanreotide autogel over 48 weeks in patients with acromegaly. Clin Endocrionol 2008; 69:299-305. (Pubitemid 352009031)
14. Attanasio R, Lanzi R, Losa M, et al. Effects of lanreotide autogel on growth hormone, insulin-like growth factor-1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008; 14:846-855. This study illustrates that regression of growth hormone secreting pituitary tumors can be achieved in patients taking lanreotide in the preoperative period.
15. Higham CE, Chung TT, Lawrance J, Drake WM, Trainer PJ. Long-term experience and pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol 2009 [Epub ahead of print]
16. Jimenez C, Burman P, Abs R, et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with Pegvisomant in clinical trials. Eur J Endocrinol 2008; 159:517-523. This study illustrates that growth hormone producing pituitary tumors are prone to increase in size following somatostatin analog withdrawal. It does not appear that treatment with Pegvisomant is followed by tumor expansion.
17. Neggers SJCMN, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without Pegvisomant. J Clin Endocrinol Metab 2008; 93:3853-3859.
18. Neggers SJCMM, de Herder WW, Janssen JAMJL, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up and 86 patients. Eur J Endocrinol 2009; 160:529-533.